Details for Patent: 8,753,611

Summary for Patent: 8,753,611

Title:	Sublingual buccal effervescent
Abstract:	A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
Inventor(s):	Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
Assignee:	Cephalon LLC
Application Number:	US13/099,003
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

United States Patent 8,753,611: Scope, Claim Architecture, and US Landscape for Oral Mucosa-Activated Effervescent Delivery

US Patent 8,753,611 is directed to a method of administering a systemically distributable pharmaceutical agent across the oral mucosa using a solid oral dosage form that (i) contains pH adjusting basic substances, (ii) contains saliva-activated effervescent couples with defined acid/base pairings, and (iii) avoids incorporation of the medicament into materials that would block mucosal uptake. The claims are written to cover delivery to buccal, sublingual, and gingival sites via dissolution after saliva activates the effervescent couple.

The claim set is broad at the “method” level (no limitation to a specific active ingredient), then narrows through defined excipient compositions and effervescence metrics. Dependent claims create additional coverage for site-specific placement (cheek, beneath tongue, between upper lip and gum), and for adding bioadhesives and conventional formulation auxiliaries (glidants, binders, lubricants, sweeteners, flavors, colorants). Separate dependent claims expand the covered active classes to include peptides/proteins/oligonucleotides, and list “typical” drug categories that can be delivered systemically by the claimed route.

What the independent claim actually covers

What is claimed in claim 1?

Claim 1 recites a three-part method:

A. Provide a solid oral dosage form containing (all of the following):

1. Orally administerable medicament present in an amount “pharmaceutically effective for buccal mucosal, gingival, or sublingual mucosal administration.”
2. At least one pH adjusting substance, which is a base selected from:
   • sodium carbonate
   • potassium carbonate
   • magnesium carbonate
   • disodium hydrogen phosphate
   • sodium dihydrogen phosphate
   • dipotassium hydrogen phosphate
   • potassium dihydrogen phosphate
3. At least one saliva activated effervescent couple sufficient to increase absorption across the oral mucosa, where the effervescent couple comprises:
   • an acid selected from citric, tartaric, malic, fumaric, adipic, succinic acid
   • a base selected from sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, magnesium carbonate
4. The medicament is not substantially encompassed by or dispersed in a material that prevents absorption across the oral mucosa.

B. Place the solid dosage form in the mouth so that saliva activates the effervescent couple in the tablet.

C. Hold and dissolve in the mouth so the effervescent couple promotes absorption across the oral mucosa.

How claim 1 constrains formulation while staying broad

Claim 1 is broad on:

• the medicament identity (not limited, except dependent claims list categories and classes), and
• the dosage form type (“solid oral dosage form” capable of saliva activation and dissolution).

Claim 1 is narrow on:

• the exact set of pH-adjusting bases,
• the exact set of acid/base components usable in the saliva-activated effervescent couple,
• the requirement that the medicament is not trapped in an absorption-blocking material, and
• the mechanism tie between saliva-activated effervescence and absorption.

That mix indicates the patent is positioned to defend around specific excipient chemistries and formulation constraints, not around any single drug.

Dependent claims: where coverage expands and where it narrows

What sites are explicitly covered?

Claim 2–4 specify placement and corresponding mucosa region:

• Claim 2 (buccal): dissolve “adjacent a cheek.”
• Claim 3 (sublingual): dissolve “beneath the tongue.”
• Claim 4 (gingival): dissolve “between the upper lip and gum.”

These do not change the excipient composition requirement from claim 1, but they strengthen enforceability by spelling out physical administration behaviors.

What formulation add-ons increase IP value?

Claim 5: the solid dosage form further includes a bioadhesive to increase contact time with oral mucosa.

Claim 6: the solid dosage form further includes glidants, lubricants, binders, sweeteners, flavoring, and coloring components.

These dependent claims likely matter in freedom-to-operate (FTO) screening because many oral solid dosage forms use exactly these excipient classes. Although the claims do not specify amounts, inclusion of such conventional excipients does not avoid infringement if the claim 1 components are present.

What active ingredient classes are covered?

Claim 7 lists a broad set of orally deliverable drug categories (examples include analgesics, anti-inflammatories, antipyretics, antibiotics/antimicrobials, laxatives, antihistamines, antiasthmatics, antihyperactives, antihypertensives, tranquilizers, decongestants, beta blockers).

Claim 8 explicitly extends coverage to:

• peptides
• proteins
• oligonucleotides

This is significant because many peptide/protein therapeutics face oral bioavailability barriers; claim 8 supports the patent’s thesis that the combination of effervescence + pH adjustment can enhance systemic uptake through oral mucosa.

Effervescent couple quantitative boundaries

Claim 9–11 add composition and gas-evolution parameters:

• Claim 9: effervescent couple present at about 5% to 95% by weight
• Claim 10: effervescent couple present at about 30% to 80% by weight
• Claim 11: effervescent couple sufficient to evolve gas about 5 cm to about 30 cm

The gas evolution “cm” metric is consistent with test methods that measure displacement/volume or gas height in a standardized setup. Claim scope turns on whether the effervescence in the claimed tablet produces gas in that range and whether that measurement is tied to the “saliva-activated” couple.

Scope map: what variants still fall inside or outside claim 1

Coverage is likely retained if:

• the formulation uses any of the listed acids paired with any of the listed effervescent bases;
• the pH adjusting component is from the listed carbonate/phosphate bases;
• the tablet is solid and placed in the mouth for saliva to activate and cause dissolution at the target oral mucosa site;
• the medicament is not encapsulated/dispersed in a matrix that blocks mucosal absorption.

Coverage is likely lost if:

• the effervescent acid or base is outside the enumerated lists (for example, using non-listed organic acids or bases would avoid the exact “selected from” limitation);
• the pH adjusting substance is not one of the enumerated bases;
• the medicament is substantially encompassed/dispersed in a barrier material that prevents absorption across oral mucosa;
• administration does not use saliva activation and dissolution to drive absorption across the oral mucosa.

This is a classic “composition-limitation + method-of-use” pattern: the enumerated ingredient lists act as hard claim boundaries even when the therapeutic agent varies.

Patent landscape: where infringement and workaround pressure will concentrate

Core competitive risk zone

For companies developing oral mucosa delivery systems, the highest risk zone is products that:

1. use a saliva-triggered effervescent acid/base system from the exact enumerated sets, and
2. include an additional pH adjusting basic substance from the enumerated carbonate/phosphate list, and
3. formulate a solid dosage that dissolves to promote systemic absorption without a barrier matrix.

This creates a convergence risk with many existing “effervescent” buccal/sublingual product designs, especially those aiming to increase permeability or dissolution-driven uptake.

Workaround vectors that can reduce claim 1 exposure

Given the strict “selected from” constraints, practical workaround levers include:

• changing effervescent pair components to non-enumerated acids/bases;
• using pH adjustment chemistry outside the enumerated list;
• using barrier/dispersing matrices that “prevent absorption” (or more precisely, that create a substantive reduction that a court would characterize as “prevents absorption,” which may be a dangerous and fact-dependent route); or
• switching from saliva-activated effervescence as the absorption-promoting mechanism.

Downstream design-around likely targeted by competitors

The dependent claims add enforceability through:

• explicit site placement (cheek/tongue/gingiva),
• bioadhesive inclusion (common in oral mucosal dosage forms),
• conventional excipients (hard to avoid),
• and quantitative effervescent ranges and gas-evolution measurement targets.

Competitors can still pursue non-infringing oral mucosa products, but the patent’s boundaries suggest a focus on replacing the chemical pairings rather than merely changing flavoring, binders, or dosage geometry.

Claim strength levers and likely enforcement posture

Strength levers

• The independent claim is tied to specific enumerated excipient chemistries, which makes infringement easier to prove when product specs and excipient sourcing align.
• The method claims include administration steps (place in mouth, saliva activates, hold/dissolve) that map to user instructions and patient behavior.
• Dependent claims add site-specific dissolution placements and measurable effervescent parameters.

Weakness levers

• The patent does not specify:
  • particular dosages of effervescent components in mg terms (it uses weight % and gas evolution range instead),
  • a specific dosage form architecture (tablet vs film vs multilayer) beyond “solid oral dosage form.”
• The language “not substantially encompassed by or dispersed in a material that prevents absorption” can become a factual and expert-driven boundary question for formulation trapping.

Practical interpretation for product teams and investors

Product specifications to audit for infringement risk

For any oral mucosa system intended for systemic delivery, audit:

• The identities of the effervescent acid and base used (must match the enumerated acid and base sets).
• The identity of any additional pH adjusting base (must match the enumerated carbonate/phosphate list).
• Whether the formulation uses any matrix/excipient that could be argued to “prevent absorption” by trapping the medicament.
• The expected saliva-activation behavior and whether dissolution and holding practices drive absorption.
• The formulation’s effervescent couple load and measured gas evolution in the claimed ranges (weight % and “cm” gas evolution metric).
• Whether instructions or labeling effectively induce cheek/buccal, sublingual, or gingival placement that matches claims 2–4.

Key Takeaways

• US 8,753,611 is a method-of-administration patent for systemic oral mucosa delivery using a solid dosage form with saliva-activated effervescent couples using enumerated acid and base lists, plus enumerated pH adjusting bases.
• The claims cover buccal, sublingual, and gingival administration via saliva activation and dissolution, with dependent claims locking in specific placement behaviors.
• The strongest claim boundaries are the exact excipient selections and the requirement that the medicament is not dispersed/encompassed in an absorption-preventing material.
• Dependent claims broaden asset value by covering bioadhesive use, typical tablet excipients, peptides/proteins/oligonucleotides, and quantified effervescence (weight % and gas evolution range).

FAQs

1. Is the patent limited to a specific active pharmaceutical ingredient?
   Claim 1 is not limited to a specific API; it covers “at least one orally administerable medicament” meeting the route and composition constraints. Dependent claims list drug classes and specifically include peptides, proteins, and oligonucleotides.

2. Does the patent require both a pH adjusting base and a saliva-activated effervescent couple?
   Yes. Claim 1 requires at least one pH adjusting substance selected from a defined list of bases, and at least one saliva activated effervescent couple with enumerated acids and bases.

3. What determines whether a product falls into the claimed effervescence scope?
   Claim 9–11 require specified ranges for effervescent couple weight percent and a gas-evolution metric (about 5 cm to about 30 cm), tied to saliva activation and absorption promotion.

4. Are typical tablet excipients like binders and lubricants covered?
   Claim 6 covers inclusion of glidants, lubricants, binders, sweeteners, flavoring, and coloring components, meaning these do not avoid infringement if the claim 1 composition requirements are met.

5. How do the dependent claims affect infringement analysis for buccal vs sublingual vs gingival dosing?
   Claims 2–4 add placement-specific dissolution behaviors. If a product’s intended use and instructions lead users to dissolve near a cheek, beneath the tongue, or between the upper lip and gum, it aligns with those dependent claims while still requiring claim 1 composition elements.

References

[1] United States Patent 8,753,611. (n.d.). Claims as provided in user prompt.

Drugs Protected by US Patent 8,753,611

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,753,611

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	350017
Austria	433745
Austria	434432
Austria	548028
Australia	4019400
Australia	4488700
Canada	2333375